Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055958 | 0.86 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL24010101 | 0.85 | PTGS2 (0.55) | PTGS2SMN1; SMN2KMT2APTGS1MEP1B | |
| SCHEMBL13211247 | 0.85 | SMN1; SMN2 (0.59) | PTGS2SMN1; SMN2POLBTSHRMAPK1 | |
| SCHEMBL29015043 | 0.85 | PTGS2 (0.54) | PTGS2SMN1; SMN2KMT2APTGS1MEP1B | |
| SCHEMBL28552857 | 0.83 | PTGS2 (0.53) | PTGS2KMT2APTGS1MEP1BPOLB | |
| SCHEMBL1093129 | 0.83 | PTGS2 (0.53) | PTGS2KMT2APTGS1MEP1BPOLB | |
| SCHEMBL2121926 | 0.83 | PTGS2 (0.68) | PTGS2KMT2APTGS1 | |
| SCHEMBL647351 | 0.83 | MEP1B (0.55) | PTGS2SMN1; SMN2KMT2APTGS1MEP1B | |
| SCHEMBL8055955 | 0.82 | PTGS2 (0.63) | PTGS2SMN1; SMN2PTGS1 | |
| SCHEMBL862980 | 0.82 | POLB (0.73) | PTGS2SMN1; SMN2PTGS1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (CH) | 2017-12-28 | — | — | US | disclosed |
| WO-2013066869-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2012037393-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010048149-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-7687492-B2 | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-30 | — | — | US | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| EP-1945608-A1 | SYNTHESIS OF METHYLSULPHONYL BENZENE COMPOUNDS | Peakdale Molecular Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
| WO-2007054668-A1 | SYNTHESIS OF METHYLSULPHONYL BENZENE COMPOUNDS | PEAKDALE MOLECULAR LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054668-A1 | SYNTHESIS OF METHYLSULPHONYL BENZENE COMPOUNDS | PEAKDALE MOLECULAR LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| EP-1756074-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005108382-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | PTGS2 1191/4885SMN1; SMN2 2213/4885KMT2A 3444/4885 |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | PTGS2 759/4885SMN1; SMN2 4014/4885KMT2A 3949/4885 |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA6, CHRNA5 | PTGS2 4135/4885SMN1; SMN2 404/4885KMT2A 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.